tradingkey.logo
tradingkey.logo
Search

Hemab Therapeutics Holdings Ord Shs (Proposed)

COAG
Add to Watchlist
32.370USD
+4.650+16.77%
Close 06/26, 16:00ETQuotes delayed by 15 min
1.29BMarket Cap
--P/E TTM
You can access the annual and quarterly cash flow statements of Hemab Therapeutics Holdings Ord Shs (Proposed) to evaluate its financial soundness and stability.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
Operating cash flows (indirect method)
Cash flow from continuing operating activities
---21.58M
Net income from continuing operations
---22.69M
Operating gains losses
--73.00K
Other non-cash items
---663.00K
Change in working capital
--375.00K
-Change in prepaid expenses
--1.17M
-Change in other current assets
---1.02M
-Change in other current liabilities
--0.00
Cash from non-recurring investing activities
Cash from operating activities
---21.58M
Investing cash flow
Net cash from continuing investing activities
--112.00K
Capital expenditures
--112.00K
Net cash flow from disposal of fixed assets
--112.00K
Net cash flow from investment products
---15.73M
Cash from non-current investing activities
Net cash flow from investing activities
---15.85M
Financing cash flow
Cash flow from continuous financing activities
---460.00K
Net cash flow from debt Issuance/repayment
---46.00K
Net cash flow from other financing activities
---414.00K
Net cash from non-recurrent financing activities
Net cash from financing activities
---460.00K
Net cash flow
Beginning cash balance
--87.97M
Current period cash flow changes
---38.11M
Effect of exchange rate changes
---223.00K
Ending cash balance
--49.86M
Free cash flow
---21.70M
Currency unit
USD
Audit opinions
--

FAQs

What is the cash flow statement?

This report tracks the movement of cash into and out of the business, covering operating, investing, and financing activities. It highlights how well the company manages cash to support growth and meet its obligations.
KeyAI